Brainstorm Cell Therapeutics Inc.
BCLI
Rank in Stocks
#28610
Brainstorm Cell Therapeutics Inc. (BCLI) is a biotechnology firm dedicated to... Brainstorm Cell Therapeutics Inc. (BCLI) is a biotechnology firm dedicated to the development and commercialization of personalized, autologous cellular therapies. These innovative treatments are specifically designed to address neurodegenerative diseases. At the heart of its strategy is the proprietary NurOwn cell therapy platform. This platform employs sophisticated cell culture techniques to prompt mesenchymal stem cells, derived from the patient's own bone marrow, to produce high concentrations of neurotrophic factors. This process aims to regulate neuroinflammatory and neurodegenerative disease mechanisms, bolster the survival of neurons, and ultimately enhance neurological function. NurOwn is currently undergoing significant clinical development, having completed a Phase III clinical trial for Amyotrophic Lateral Sclerosis (ALS). Additionally, it has successfully advanced through Phase II clinical trials for both progressive multiple sclerosis and Alzheimer's disease, with potential applications being explored for other neurodegenerative conditions. To support its therapeutic pipeline, the company has established a manufacturing partnership with Catalent for NurOwn. Incorporated in 2000, the company initially operated as Golden Hand Resources Inc. before adopting the name Brainstorm Cell Therapeutics Inc. in November 2004. Its corporate headquarters are situated in New York, New York.
Share Price
$0.949
Last synced: 2026-11-09
Market Cap
$10.47M
Change (1 day)
5.44%
Change (1 year)
43.79%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Brainstorm Cell Therapeutics Inc. (BCLI)
Category
Healthcare
Earnings for Brainstorm Cell Therapeutics Inc. (BCLI)
Earnings in Jun 2026 TTM: $-10.52M
According to Brainstorm Cell Therapeutics Inc.'s latest financial reports, its current earnings (TTM) are $-10.52M. In 2025 the company earned $-10.31M, a decrease compared to its 2024 earnings of $11.62M. The earnings shown on this page are earnings before interest and taxes, or EBIT.
Earnings history for Brainstorm Cell Therapeutics Inc. from 2002 to 2026
Earnings at the end of each year
| Year | Earnings | Change |
|---|---|---|
| 2026 (TTM) | $-10.52M | 2.09% |
| 2025 | $-10.31M | -188.68% |
| 2024 | $11.62M | -167.61% |
| 2023 | $-17.19M | -29.18% |
| 2022 | $-24.28M | -0.74% |
| 2021 | $-24.46M | -23.12% |
| 2020 | $-31.81M | 36.80% |
| 2019 | $-23.25M | 66.71% |
| 2018 | $-13.95M | 181.66% |
| 2017 | $-4.95M | -0.60% |
| 2016 | $-4.98M | -41.31% |
| 2015 | $-8.49M | -8.20% |
| 2014 | $-9.25M | 89.70% |
| 2013 | $-4.87M | 42.31% |
| 2012 | $-3.43M | -12.47% |
| 2011 | $-3.91M | 63.04% |
| 2010 | $-2.40M | 34.76% |
| 2009 | $-1.78M | -48.70% |
| 2008 | $-3.47M | -44.39% |
| 2007 | $-6.24M | 19.86% |
| 2006 | $-5.21M | -72.34% |
| 2005 | $-18.83M | 25,594.85% |
| 2004 | $-73.30K | 0.00% |
| 2003 | $-73.30K | 124.22% |
| 2002 | $-32.69K | 0.00% |
Earnings for similar companies or competitors
| Company | Earnings | Earnings Difference | Country |
|---|---|---|---|
| $4.76B | -45,333.80% |
US
|
|
| $-2.73B | 25,836.13% |
US
|
|
| $-4.02B | 38,069.52% |
AU
|
|
| $2.83B | -26,956.33% |
BE
|
|
| $1.50B | -14,326.78% |
NL
|
Questions about Brainstorm Cell Therapeutics Inc.'s net income
What is Brainstorm Cell Therapeutics Inc.'s net income?
Brainstorm Cell Therapeutics Inc.'s net income over the last twelve months is $-10.52M, as of Jun 2026.
What was Brainstorm Cell Therapeutics Inc.'s net income in 2025?
In 2025, Brainstorm Cell Therapeutics Inc.'s net income was $-10.31M, compared with $11.62M in 2024.
How has Brainstorm Cell Therapeutics Inc.'s net income changed since 2020?
From 2020 to 2025, Brainstorm Cell Therapeutics Inc.'s net income was highest in 2024 ($11.62M) and lowest in 2020 ($-31.81M).
How does Brainstorm Cell Therapeutics Inc.'s net income compare with similar companies?
Brainstorm Cell Therapeutics Inc.'s net income ($-10.52M) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with $4.76B.